Hear from Prof Fiona Thistlethwaite (Christie) and our UK Medical Head, Dr David Harland, about the key updates from ESMO 2024 and their significance for UK clinical practice.
At AstraZeneca, we are dedicated to transforming care. We work closely with the NHS and other partners to identify and address key challenges in patient pathways, from early detection to treatment and ongoing support. Learn more here about our partnerships with the NHS to improve oncology pathways across the UK.
This website is intended for UK healthcare professionals only
© AstraZeneca 2025. All rights reserved.
GB-72601 December 2025
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033.
© AstraZeneca 2025. All rights reserved.
GB-72601 December 2025
The content on this website is intended for UK Healthcare Professionals only. The website contains both promotional and non-promotional content.
